815 related articles for article (PubMed ID: 21128245)
1. Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis.
Ertle J; Dechêne A; Sowa JP; Penndorf V; Herzer K; Kaiser G; Schlaak JF; Gerken G; Syn WK; Canbay A
Int J Cancer; 2011 May; 128(10):2436-43. PubMed ID: 21128245
[TBL] [Abstract][Full Text] [Related]
2. Steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH.
Salomao M; Yu WM; Brown RS; Emond JC; Lefkowitch JH
Am J Surg Pathol; 2010 Nov; 34(11):1630-6. PubMed ID: 20975341
[TBL] [Abstract][Full Text] [Related]
3. Decreased immunoexpression of survivin could be a potential marker in human non-alcoholic fatty liver disease progression?
Stefano JT; de Oliveira CP; Corrêa-Giannella ML; Soares IC; Kubrusly MS; Bellodi-Privato M; de Mello ES; de Lima VM; Carrilho FJ; Alves VA
Liver Int; 2011 Mar; 31(3):377-85. PubMed ID: 21108736
[TBL] [Abstract][Full Text] [Related]
4. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
Perumpail RB; Wong RJ; Ahmed A; Harrison SA
Dig Dis Sci; 2015 Oct; 60(10):3142-8. PubMed ID: 26250831
[TBL] [Abstract][Full Text] [Related]
5. Non-alcoholic fatty liver disease associated with hepatocellular carcinoma: An increasing concern.
Dhamija E; Paul SB; Kedia S
Indian J Med Res; 2019 Jan; 149(1):9-17. PubMed ID: 31115369
[TBL] [Abstract][Full Text] [Related]
6. Nonalcoholic fatty liver disease, metabolic risk factors, and hepatocellular carcinoma: an open question.
Streba LA; Vere CC; Rogoveanu I; Streba CT
World J Gastroenterol; 2015 Apr; 21(14):4103-10. PubMed ID: 25892859
[TBL] [Abstract][Full Text] [Related]
7. Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis.
Mohamad B; Shah V; Onyshchenko M; Elshamy M; Aucejo F; Lopez R; Hanouneh IA; Alhaddad R; Alkhouri N
Hepatol Int; 2016 Jul; 10(4):632-9. PubMed ID: 26558795
[TBL] [Abstract][Full Text] [Related]
8. Genomic aspects of NAFLD pathogenesis.
Naik A; Košir R; Rozman D
Genomics; 2013 Aug; 102(2):84-95. PubMed ID: 23545492
[TBL] [Abstract][Full Text] [Related]
9. Hepatocarcinogenesis in non-alcoholic fatty liver disease in Japan.
Tokushige K; Hashimoto E; Kodama K
J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():88-92. PubMed ID: 24251711
[TBL] [Abstract][Full Text] [Related]
10. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
[TBL] [Abstract][Full Text] [Related]
11. The epidemiology of non-alcoholic fatty liver disease.
Bellentani S
Liver Int; 2017 Jan; 37 Suppl 1():81-84. PubMed ID: 28052624
[TBL] [Abstract][Full Text] [Related]
12. Utilization of animal models to investigate nonalcoholic steatohepatitis-associated hepatocellular carcinoma.
Wu J
Oncotarget; 2016 Jul; 7(27):42762-42776. PubMed ID: 27072576
[TBL] [Abstract][Full Text] [Related]
13. Trends in burden of cirrhosis and hepatocellular carcinoma by underlying liver disease in US veterans, 2001-2013.
Beste LA; Leipertz SL; Green PK; Dominitz JA; Ross D; Ioannou GN
Gastroenterology; 2015 Nov; 149(6):1471-1482.e5; quiz e17-8. PubMed ID: 26255044
[TBL] [Abstract][Full Text] [Related]
14. Characteristics and diagnosis of NAFLD/NASH.
Hashimoto E; Taniai M; Tokushige K
J Gastroenterol Hepatol; 2013 Dec; 28 Suppl 4():64-70. PubMed ID: 24251707
[TBL] [Abstract][Full Text] [Related]
15. Resection of NAFLD/NASH-related Hepatocellular Carcinoma (HCC): Clinical Features and Outcomes Compared with HCC Due to Other Etiologies.
Pal Chaudhary S; Reyes S; Chase ML; Govindan A; Zhao L; Luther J; Bhan I; Bethea E; Franses JW; Paige Walsh E; Anne Dageford L; Kimura S; Elias N; Yeh H; Markman J; Bozorgzadeh A; Tanabe K; Ferrone C; Zhu AX; Andersson K; Thiim M; Antonio Catalano O; Kambadakone A; Vagefi PA; Qadan M; Pratt D; Hashemi N; Corey KE; Misdraji J; Goyal L; Clark JW
Oncologist; 2023 Apr; 28(4):341-350. PubMed ID: 36763374
[TBL] [Abstract][Full Text] [Related]
16. Clinical features of hepatocellular carcinoma associated with nonalcoholic fatty liver disease: a review of human studies.
Oda K; Uto H; Mawatari S; Ido A
Clin J Gastroenterol; 2015 Feb; 8(1):1-9. PubMed ID: 25575848
[TBL] [Abstract][Full Text] [Related]
17. Hepatocellular carcinoma in non-alcoholic fatty liver disease: an emerging menace.
Baffy G; Brunt EM; Caldwell SH
J Hepatol; 2012 Jun; 56(6):1384-91. PubMed ID: 22326465
[TBL] [Abstract][Full Text] [Related]
18. Definition and natural history of metabolic steatosis: clinical aspects of NAFLD, NASH and cirrhosis.
Serfaty L; Lemoine M
Diabetes Metab; 2008 Dec; 34(6 Pt 2):634-7. PubMed ID: 19195623
[TBL] [Abstract][Full Text] [Related]
19. Characteristics of hepatocellular carcinoma in cirrhotic and non-cirrhotic non-alcoholic fatty liver disease.
Leung C; Yeoh SW; Patrick D; Ket S; Marion K; Gow P; Angus PW
World J Gastroenterol; 2015 Jan; 21(4):1189-96. PubMed ID: 25632192
[TBL] [Abstract][Full Text] [Related]
20. Non-B, non-C hepatocellular carcinoma (Review).
Nishikawa H; Osaki Y
Int J Oncol; 2013 Nov; 43(5):1333-42. PubMed ID: 23969900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
